Evidence map›Paper›PMID 42208543›Full record

ArticleCell reports. Medicine2026

Intravenous human umbilical cord-derived mesenchymal stem cell transplantation for ischemic stroke (MERIT): A phase 1 trial.

Lili Cui, Ming Xiao, Qian Zhang, Haijie Liu, Yi Ren, Gaoting Ma, Da Zhou, Qingfeng Ma, Hui Yao, Ming Lin and 11 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05697718 (A Phase I Study of Safety and Tolerability of Single-dose Human Umbilical Cord Mesenchymal Stem Cell), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05697718 phase1completednot on this map

A Phase I Study of Safety and Tolerability of Single-dose Human Umbilical Cord Mesenchymal Stem Cell (IxCell hUC-MSC-S) in Patients With Convalescent Phase of Ischemic Stroke

TypeinterventionalSponsorShanghai IxCell Biotechnology Co., LTDRan2023 to 2024Enrolled18ConditionsIschemic StrokeArmsMSC
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lili CuiDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Ming XiaoShanghai IxCell Biotech Co. Ltd, Shanghai 201203, China.
Qian ZhangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Haijie LiuDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Yi RenDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Gaoting MaDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Da ZhouDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Qingfeng MaDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Hui YaoDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Ming LinDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Daiquan GaoDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Linlin YeDepartment of Rehabilitation, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Ran WangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Yelin WangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Lan ZhangDepartment of Pharmacology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Lianmei ZhongDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Ge GaoShanghai IxCell Biotech Co. Ltd, Shanghai 201203, China.
Jieli ChenDepartment of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin 300000, China.
Jukka JolkkonenA.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland.
Johannes BoltzeSchool of Life Sciences, University of Warwick, Coventry CV47AL, UK.
Junwei HaoDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Beijing Municipal Geriatric Medical Research Center, Beijing 100053, China; Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing 100069, China. Electronic address: haojunwei@vip.163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Umbilical cord-derived mesenchymal stem cells (UC-MSCs) hold promise as a potential therapy for ischemic stroke, but the optimal transplantation strategy remains to be explored. This open-label, single-arm, phase 1 study enrolls 18 patients with subacute ischemic stroke and National Institutes of Health Stroke Scale (NIHSS) scores of 6-20 (median, 9; interquartile range, 8-12). The patients receive a single intravenous transplantation of 50, 100, or 200 million UC-MSCs (n = 6 for each dose) and are followed for 24 weeks. The primary outcome is safety and tolerability, with secondary assessment of preliminary efficacy and exploratory analyses of immunological changes. Possible treatment-related adverse events include dizziness, nausea, sweating, fatigue, and epilepsy. No serious adverse event occurs. A reduction in NIHSS score by 1-5 points is observed in 14 patients during follow-up. In conclusion, intravenous administration of UC-MSCs is well-tolerated in subacute ischemic stroke. The trial is registered on ClinicalTrials.gov (NCT05697718).

Indexed as

Brain IschemiaIschemic StrokeMesenchymal Stem CellsMesenchymal Stem Cell TransplantationStrokeUmbilical CordAdministration, IntravenousAdultAgedFemaleHumansMaleMiddle AgedTreatment Outcomeefficacyimmunological changesischemic strokemesenchymal stem cellsafety

Identifiers

PMID42208543
PMCPMC13293954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.